35 phenotypes from 2 alleles in 2 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Mocs2tm1(KOMP)Vlcg/Mocs2+ involves: C57BL/6NTac	increased neuron apoptosis	J:242197
Mocs2tm1(KOMP)Vlcg/Mocs2tm1(KOMP)Vlcg involves: C57BL/6NTac	abnormal blood homeostasis	J:242197
	abnormal enzyme/coenzyme activity	J:242197
	abnormal hair growth	J:242197
	abnormal kidney collecting duct morphology	J:242197
	abnormal kidney pelvis morphology	J:242197
	abnormal vibrissa morphology	J:242197
	curly vibrissae	J:242197
	cystinuria	J:242197
	cystolithiasis	J:242197
	decreased blood uric acid level	J:242197
	decreased body size	J:242197
	decreased urine uric acid level	J:242197
	erythrocyturia	J:242197
	flaky skin	J:242197
	hemoglobinuria	J:242197
	increased circulating creatinine level	J:242197
	increased neuron apoptosis	J:242197
	increased urine hypoxanthine level	J:242197
	increased urine protein level	J:242197
	increased urine xanthine level	J:242197
	ischuria	J:242197
	kidney failure	J:242197
	muscle weakness	J:242197
	nephrolithiasis	J:242197
	postnatal growth retardation	J:242197
	postnatal lethality, complete penetrance	J:242197
	slow postnatal weight gain	J:242197
	urinary bladder obstruction	J:242197
	weakness	J:242197
	wrinkled skin	J:242197
Mocs2tm1b(EUCOMM)Wtsi/Mocs2+ C57BL/6N-Mocs2tm1b(EUCOMM)Wtsi/Ieg	decreased body length	J:211773
	decreased circulating sodium level	J:211773
	increased fasting circulating glucose level	J:211773
	persistence of hyaloid vascular system	J:211773
Mocs2tm1b(EUCOMM)Wtsi/Mocs2tm1b(EUCOMM)Wtsi C57BL/6N-Mocs2tm1b(EUCOMM)Wtsi/Ieg	preweaning lethality, complete penetrance	J:211773